Products Vorinostat + Pegylated Liposomal Doxorubicin (PLD), Doxil
Vorinostat + Pegylated Liposomal Doxorubicin (PLD), Doxil Phase 1/2 Terminated ⚡ Active Relapsed Lymphomas, Refractory Lymphomas
Jan 1, 2009 → Sep 1, 2011
About Vorinostat + Pegylated Liposomal Doxorubicin (PLD), Doxil Vorinostat + Pegylated Liposomal Doxorubicin (PLD), Doxil is a phase 1/2 stage product being developed by Merck for Relapsed Lymphomas. The current trial status is terminated. This product is registered under clinical trial identifier NCT00785798. Target conditions include Relapsed Lymphomas, Refractory Lymphomas.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT00785798 Phase 1/2 Terminated Jan 1, 2009 Sep 1, 2011 Relapsed Lymphomas
Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 VIP152 + BTKi Vincerx Pharma Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 AC220 Daiichi Sankyo Phase 1 Valemetostat Tosylate Daiichi Sankyo Phase 2 Linsitinib Astellas Pharma Phase 2 AGS67E Astellas Pharma Phase 1 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib Eisai Phase 2 Tazemetostat Eisai Phase 2 Tazemetostat Eisai Phase 1 Eribulin mesylate Eisai Phase 2 ME-401 Kyowa Kirin Phase 1 KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6 Kyowa Kirin Phase 1 Mogamulizumab Kyowa Kirin Phase 2 ONO-4685 Ono Pharmaceutical Phase 1 ONO-4685 Ono Pharmaceutical Phase 1 Tirabrutinib + Rituximab + Temozolomide Ono Pharmaceutical Phase 3
Other Products from Merck